SCHEMBL11353

SCHEMBL11353

Cn1nc(N)cc1C#Cc1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2B6 P20813 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2E1 P05181 2/20 0.44
CYP3A4 P08684 2/20 0.44
GRM5 P41594 7/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C8 P10632 1/20 0.43
CHRNB2 P17787 3/20 0.42
CHRNA4 P43681 3/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11562 0.78 GRM5 (0.42) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL11005 0.75 ABL1 (0.53) CYP2A6CYP2C9CYP2B6CYP2C19GRM5
SCHEMBL3796332 0.73 CYP2A6 (0.67) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL2806708 0.69 MEN1 (0.55) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL13907278 0.69 CYP2A6 (0.62) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10322 0.69 CYP2A6 (0.51) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL15617603 0.68 CYP2A6 (0.51) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL401836 0.67 GRM5 (0.64) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL31673222 0.67 GRM5 (0.64) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL24416463 0.67 GRM5 (0.56) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488511-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Vertex Pharmaceuticals Incorporated (US) 2012-08-22 EP disclosed
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 US disclosed
WO-2011041634-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 WO disclosed
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081316-A1 PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIK3CG CYP2A6 2358/4885CYP2C9 2078/4885CYP2B6 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.